Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
2024年4月18日 - 9:00PM
ビジネスワイヤ(英語)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it will report financial
results for the first quarter ending March 31, 2024 on Thursday,
May 2, 2024, before the U.S. financial markets open.
Management will provide an update on the Company and discuss
first quarter 2024 results as well as expectations for the future
via conference call on Thursday, May 2, 2024 at 8:30 am ET. To
access the call, please register online at
https://register.vevent.com/register/BI0abdd195e81a43d9ac0c44fe9d789f86.
Participants are requested to register a day in advance or at a
minimum 15 minutes before the start of the call. A replay of the
call will be available two hours after the call and archived on the
same web page for six months.
A live audio webcast of the call will be available on the
Investors section of the Company’s website at
www.alnylam.com/events. An archived webcast will be available on
the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation
of RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and prevalent diseases with unmet need. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach yielding transformative
medicines. Since its founding in 2002, Alnylam has led the RNAi
Revolution and continues to deliver on a bold vision to turn
scientific possibility into reality. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), AMVUTTRA®
(vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and
Leqvio® (inclisiran), which is being developed and commercialized
by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates
that are in late-stage development. Alnylam is executing on its
“Alnylam P5x25” strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or
on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240418150859/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340 Josh Brodsky (Investors)
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
過去 株価チャート
から 4 2024 まで 5 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
過去 株価チャート
から 5 2023 まで 5 2024